- Home
- AGEN vs EML Comparison
AGEN vs EML Comparison
Compare AGEN & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | EML |
|---|---|---|
| Founded | 1994 | 1858 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 119.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | EML |
|---|---|---|
| Price | $3.34 | $18.55 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 983.6K | 16.0K |
| Earning Date | 03-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 2.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.19 |
| Revenue | $106,829,000.00 | ★ $258,121,226.00 |
| Revenue This Year | $23.68 | $1.56 |
| Revenue Next Year | $23.17 | $7.00 |
| P/E Ratio | ★ N/A | $17.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $18.01 |
| 52 Week High | $7.34 | $29.55 |
Technical Indicators
Market Signals| Indicator | AGEN | EML |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 44.19 |
| Support Level | $3.01 | $18.01 |
| Resistance Level | $4.87 | $19.06 |
| Average True Range (ATR) | 0.36 | 0.64 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 15.95 | 18.73 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.